Moderna’s melanoma therapy shows 83% response rate in trial

Moderna reported encouraging Phase 2 data for mRNA-4359 plus pembrolizumab in first-line metastatic melanoma, with an 83% overall response rate, 92% disease control rate, and no new immune-related safety signals. The FDA also granted Fast Track designation for the program, while Moderna separately resolved global patent litigation with a $950 million payment due by July 2026 and up to $1.3 billion more contingent on future decisions. Jefferies reiterated a Hold with a $37 price target.

Analysis

The market is likely pricing Moderna on a “platform reset” rather than a single asset update: the melanoma signal matters less for near-term revenue than for validating that the company can still generate durable immuno-oncology readouts after years of skepticism. The second-order implication is multiple expansion optionality if investors begin underwriting a broader oncology franchise, but that only sticks if subsequent cohorts reproduce response durability and the biomarker gradient holds across larger, messier populations.

The patent settlement is the more material swing factor for the stock over the next 6-12 months because it converts an open-ended legal overhang into a known cash call. That reduces tail-risk discounting, but it also forces the market to reconcile a cleaner litigation backdrop with a still-hefty funding need for pipeline execution; in other words, less insolvency risk, more capital allocation scrutiny. ABUS is the obvious loser: the settlement likely caps litigation leverage and removes a key catalyst for a rerating.

The contrarian issue is that the stock’s year-to-date move may already reflect a lot of the “bad news is behind us” narrative, while the oncology data are still far from registrational and the cash outflow is deferred rather than erased. If the next data package does not improve on durability or expand meaningfully beyond a small biomarker-selected subset, the shares can easily revert to trading on burn rate and pipeline execution again. The upside case is a multi-quarter rerating; the downside case is that this becomes another headline-driven pop that fades once investors focus on the balance sheet and clinical sample size.

Key Decisions for Investors

• MRNA: stay tactically long only into follow-on oncology catalysts over the next 4-8 weeks; use strength to trim because the move is likely to be data-squeeze driven unless durability improves materially.
• MRNA: for accounts that need convexity, consider a risk-defined call spread rather than outright long stock — upside is tied to platform validation, but downside remains dominated by cash burn and execution risk over the next 6-12 months.
• ABUS: maintain or initiate short exposure on settlement-finalization strength; the litigation overhang is largely monetized, so the remaining thesis is weaker and the stock should lose catalyst power over 1-3 months.
• Relative value: long MRNA / short a basket of low-momentum large-cap biotech names only if you want event-driven beta to oncology validation; otherwise avoid pairing MRNA against pure cash-generating biotechs because the fundamental dispersion is still too high.
• Set a catalyst watch on the next response-durability disclosure for MRNA; if median duration or deeper follow-up is not meaningfully better than prior cohorts, fade the rally and expect reversion toward valuation support rather than growth premium.